HRH4 and Alzheimer disease: Other novel systemic therapies approved or in clinical trials for AD, but not asthma, target IL-31, OSMRß, NK1R, P2X3, H4R, IL-22, IL-17A, IL-23, OX40, CCR4, S1P, and Janus kinases [3].